TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31442484

Group type: EXPERIMENTAL
Intervention: Decision aid consisting of a video and ACP booklet
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cancer pain control
Number of subjects: 204
Study: 28575208

Group type: EXPERIMENTAL
Intervention: 12 weekly doses of directly observed isoniazid and rifapentine (3HP)
Number of subjects: 3288
Study: 26638010

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every-2-weeks (Q2W)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 305

Group type: COMPARATOR
Intervention: Double-dose rosuvastatin
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 305

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 305
Study: 25129515

Group type: EXPERIMENTAL
Intervention: 15% DEET topical repellent
Number of subjects: 4426

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 4426
Study: 23040580

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 0
Study: 19234056

Group type: EXPERIMENTAL
Intervention: High vegetable diet (8 servings of vegetables, 2-3 servings of fruits)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Energy reduction diet (reduce daily intake by 500 kcal and limit energy from fat to <or=25%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (high vegetable diet and energy reduction diet)
Number of subjects: 30
Study: 16816279

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 560

Group type: COMPARATOR
Intervention: Enhanced specialty referral
Number of subjects: 560
Study: 12790845

Group type: EXPERIMENTAL
Intervention: Single combined preoperative dose of gentamicin (160 mg) and metronidazole (500 mg)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Postoperative standard scheme of antibiotics over 7 days
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Single combined preoperative dose of gentamicin and metronidazole
Number of subjects: 288
Study: 10966992

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Number of subjects: 0
Study: 8836419

Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) as adjuvant after chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) for partial responders (PRs) after chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planned XRT in advanced disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) as salvage treatment for asymptomatic limited nodal relapse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XRT in high-dose therapy programs
Number of subjects: 0
Study: 1734801

Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine 20 mg (group F2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine 20 mg (group F3)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intramuscular saline (placebo, group P2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine 20 mg (group F1)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intramuscular saline (placebo, group P3)
Number of subjects: 89
Study: 6539662

Group type: EXPERIMENTAL
Intervention: 1.0 mg Gemeprost vaginal suppository
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31569168

Group type: EXPERIMENTAL
Intervention: Meth-ctDNA positive patients
Number of subjects: 146

Group type: COMPARATOR
Intervention: Meth-ctDNA negative patients
Number of subjects: 146
Study: 30891688

Group type: EXPERIMENTAL
Intervention: Intervention-specific counseling (n = 35)
Number of subjects: 134

Group type: COMPARATOR
Intervention: General weight counseling (n = 82)
Number of subjects: 134

Group type: COMPARATOR
Intervention: No documented weight counseling (n = 17)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Perceptions of provider empathy
Number of subjects: 134
Study: 28341108

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 every 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2 on day 1 every 3 weeks)
Number of subjects: 0
Study: 27914473

Group type: EXPERIMENTAL
Intervention: CBT-E (20 sessions over 20 weeks)
Number of subjects: 132
Study: 25089264

Group type: EXPERIMENTAL
Intervention: Mebeverine (135 mg, twice daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Mebeverine
Number of subjects: 115
Study: 20934714

Group type: EXPERIMENTAL
Intervention: Fast Track (FT) program with fluid restriction and epidural analgesia (EDA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard Care (SC) group
Number of subjects: 151
Study: 19602962

Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic blockade with lidocaine
Number of subjects: 23

Group type: COMPARATOR
Intervention: IV lidocaine
Number of subjects: 23
Study: 17467553

Group type: EXPERIMENTAL
Intervention: Long-term azithromycin administration
Number of subjects: 0
Study: 15896256

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0
Study: 12517685

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10705266

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg 3 times daily for 2 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8664560

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 1283538

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen
Number of subjects: 182

Group type: COMPARATOR
Intervention: Untreated historical group
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 182
Study: 6476499

Group type: EXPERIMENTAL
Intervention: 22% BCAA amino acid solution
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 41% BCAA amino acid solution
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (41% BCAA amino acid solution)
Number of subjects: 22
Study: 31639849

Group type: EXPERIMENTAL
Intervention: Robot‐Assisted surgery (R)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Surgery (C)
Number of subjects: 26
Study: 31462859

Group type: EXPERIMENTAL
Intervention: Customized post with stud attachment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prefabricated access post
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cast coping (nonattachment control group)
Number of subjects: 30
Study: 29958022

Group type: EXPERIMENTAL
Intervention: Closed loop insulin delivery during labor and delivery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Closed loop insulin delivery postpartum
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of maternal glucose concentration between mothers of infants with and without neonatal hypoglycemia
Number of subjects: 27
Study: 28051828

Group type: EXPERIMENTAL
Intervention: Reverdin‐Isham osteotomy (group A, 20 feet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endolog system (group B, 20 feet)
Number of subjects: 40
Study: 24561397

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (Gd-MRI) findings of enhancing herniated disc
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (Gd-MRI) findings of enhancing nerve root
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (Gd-MRI) findings
Number of subjects: 204
Study: 22659218

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 33
Study: 19592029

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg (group P)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg added to lidocaine (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (saline) solution (group S)
Number of subjects: 45
Study: 16145678

Group type: EXPERIMENTAL
Intervention: Bone marrow abnormality score decreased
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Bone marrow abnormality score increased
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Bone marrow abnormality score did not change
Number of subjects: 377

Group type: COMPARATOR
Intervention: Urinary CTX‐II levels in the highest tertile
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Decrease in urinary CTX‐II levels
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Increase in urinary CTX‐II levels
Number of subjects: 377
Study: 12198999

Group type: EXPERIMENTAL
Intervention: $5.00 incentive plus transportation costs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transportation costs only (Control)
Number of subjects: 0
Study: 10532133

Group type: EXPERIMENTAL
Intervention: Liquid diet, sennosides A and B, and a two-liter solution with PEG and electrolytes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Liquid diet plus sennosides A and B
Number of subjects: 200
Study: 7768070

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml) before one oral and one intravenous dose of cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cyclosporine (2.5 mg/kg infused for 3 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral cyclosporine (7.5 mg/kg)
Number of subjects: 0
Study: 1691392

Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI) infusion (20 ng kg‐1/min) during placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epinephrine (EPI) infusion during beta 1‐selective beta‐adrenoceptor blockade with atenolol (50 mg once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epinephrine (EPI) infusion during nonselective beta‐blockade with bopindolol (1 mg once daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI) infusion during stress tests
Number of subjects: 10
Study: 369646

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study: 29804638

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/bevacizumab (Arm 1)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/temsirolimus (Arm 2)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Ixabepilone/carboplatin/bevacizumab (Arm 3)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Historical controls (PC Arm of trial GOG209)
Number of subjects: 349
Study: 27526175

Group type: EXPERIMENTAL
Intervention: Workplace intervention
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 231
Study: 25564211

Group type: EXPERIMENTAL
Intervention: RIPC (4 × 5 min upper limb ischaemia)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No RIPC
Number of subjects: 32
Study: 23842504

Group type: EXPERIMENTAL
Intervention: Standardized orders for alcohol withdrawal (AW)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Manual order writing for alcohol withdrawal (AW)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Direct clinical experience (for AW)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Direct clinical experience (for AECOPD)
Number of subjects: 175
Study: 19937075

Group type: EXPERIMENTAL
Intervention: G1, XP Bond + Ceram-X Mono
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G2, P&B NT + Ceram-X Mono
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G3, Optibond Solo Plus + Ceram-X Mono
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: R1, Syntac Classic + Tetric EvoCeram
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: R2, Scotchbond 1 XT + Z250
Number of subjects: 40
Study: 19164821

Group type: EXPERIMENTAL
Intervention: In-person recruitment, e-mail, and community flyers
Number of subjects: 213
Study: 15795147

Group type: EXPERIMENTAL
Intervention: Epinephrine 12.5 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epinephrine 25 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epinephrine 50 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epinephrine 100 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group: bupivacaine 2.5 mg and fentanyl 25 microg only
Number of subjects: 100
Study: 14576732

Group type: EXPERIMENTAL
Intervention: High-dose anthracycline regimens, four cycles given every 15 days as induction lasting for ≤6 months.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High-dose therapy consolidation followed by autologous stem-cell transplantation (23 patients).
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard chemotherapy regimens (69 patients).
Number of subjects: 92
Study: 10868452

Group type: EXPERIMENTAL
Intervention: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during late phase II of the intestinal MMC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during phase I of the intestinal MMC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caloric liquid bolus (280 kJ)
Number of subjects: 8
Study: 9010548

Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (information-based health promotion programme)
Number of subjects: 0
Study: 1643678

Group type: EXPERIMENTAL
Intervention: pH-adjusted (pH 6.8 range 6.7-6.9) 0.75% bupivacaine with hyaluronidase
Number of subjects: 50

Group type: COMPARATOR
Intervention: plain (pH 5.4) 0.75% bupivacaine with hyaluronidase
Number of subjects: 50
Study: 6657887

Group type: EXPERIMENTAL
Intervention: Psychosomatic group therapy (including autogenic training and functional relaxation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 31729195

Group type: EXPERIMENTAL
Intervention: DMPA use (depot medroxyprogesterone acetate)
Number of subjects: 0
Study: 29476687

Group type: EXPERIMENTAL
Intervention: Aflibercept on a monthly schedule
Number of subjects: 293

Group type: COMPARATOR
Intervention: Aflibercept on a TAE schedule
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Bevacizumab on a monthly schedule
Number of subjects: 293

Group type: COMPARATOR
Intervention: Bevacizumab on a TAE schedule
Number of subjects: 293
Study: 29949332

Group type: EXPERIMENTAL
Intervention: Traditional Chinese spinal orthopedic manipulation (TCSOM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 60
Study: 25265495

Group type: EXPERIMENTAL
Intervention: 8 mmHg low pressure group (LPG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 12 mmHg standard pressure group (SPG)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 15 mmHg high pressure group (HPG)
Number of subjects: 150
Study: 22925134

Group type: EXPERIMENTAL
Intervention: Ulceration present and positive SLN
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Ulceration present
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Positive SLN
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Breslow thickness of ≥2.3 mm
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Nonextremity tumor location
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Non-SLN-positive status
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Ulceration
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Presence of ulceration and positive SLN
Number of subjects: 736
Study: 20854235

Group type: EXPERIMENTAL
Intervention: Perindopril plus indapamide (4 mg-1.25 mg/day)
Number of subjects: 11140
Study: 18439712

Group type: EXPERIMENTAL
Intervention: Apples (0.63 kcal/g energy density)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pears (0.64 kcal/g energy density)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oat cookies (3.7 kcal/g energy density)
Number of subjects: 49
Study: 15621465

Group type: EXPERIMENTAL
Intervention: New protocol (group 2) with oxytetracycline instilled in a fractionated-dose manner following frequent aspirations at 6h intervals
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard protocol (group 1) with drainage until radiological evidence of lung re-expansion and then instillation of oxytetracycline
Number of subjects: 27
Study: 12663723

Group type: EXPERIMENTAL
Intervention: Pharmacology group (adjusted by WBC, E-TGN, and E-MTX)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Control group (adjusted by WBC only)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Pharmacology group
Number of subjects: 538
Study: 11739065

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with sertraline
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sertraline without ERT
Number of subjects: 127
Study: 9403227

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8234999

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg p.o. administered for 60 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3318609

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin (1 g) 30 minutes before gastrostomy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intravenous saline as a placebo
Number of subjects: 107

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin (1 g)
Number of subjects: 107
Study: 31031076

Group type: EXPERIMENTAL
Intervention: Early mobilization at 3 hours after CIED surgery (E-motion group, EMG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard 24-hour immobilization (control group, CG)
Number of subjects: 200
Study: 29231481

Group type: EXPERIMENTAL
Intervention: Auricular point sticking treatment (adhesive fabric with vaccaria seeds pressed at specific auricular points for 3 to 5 min, administered twice daily for one week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (similar adhesive fabric at auricular points pressed for 3 to 5 min at identical time points)
Number of subjects: 60
Study: 25134056

Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF) intervention
Number of subjects: 234
Study: 23845795

Group type: EXPERIMENTAL
Intervention: Haemoconcentration (≥3% absolute increase in haematocrit)
Number of subjects: 1684
Study: 21483895

Group type: EXPERIMENTAL
Intervention: Three-implant-supported fixed dentures (ISFDs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two-implant-supported overdentures (IODs)
Number of subjects: 20
Study: 19160529

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 0
Study: 16569536

Group type: EXPERIMENTAL
Intervention: Enoxaparin followed by reteplase (group A)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Enoxaparin followed by abciximab and transfer to invasive center for optional PCI (group B)
Number of subjects: 205
Study: 12756636

Group type: EXPERIMENTAL
Intervention: SMPC (special milk protein concentrate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10912666

Group type: EXPERIMENTAL
Intervention: Interferon plus Ursodeoxycholic acid (UDCA) (13‐15 mg/kg/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Interferon plus placebo
Number of subjects: 91
Study: 9454431

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide in crystalline suspension (Volon A 80, 2.0 ml) intrathecally via lumbar puncture on the 5th postoperative day (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups were examined again 4 weeks after discharge
Number of subjects: 160
Study: 8363378

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg every 12 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous ofloxacin (400 mg every 12 h, 1-h infusion)
Number of subjects: 20
Study: 30982556

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 7106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7106
Study: 29924823

Group type: EXPERIMENTAL
Intervention: Home-based computerized cognitive training (CCT) using Lumosity, 40 training sessions (5 days/week for 8 weeks)
Number of subjects: 32
Study: 26829595

Group type: EXPERIMENTAL
Intervention: Lumina IOL
Number of subjects: 86

Group type: COMPARATOR
Intervention: Acrysof SA60AT monofocal IOL
Number of subjects: 86
Study: 24333802

Group type: EXPERIMENTAL
Intervention: Telecare (TC)
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1189
Study: 22240271

Group type: EXPERIMENTAL
Intervention: GFR retainers
Number of subjects: 85

Group type: COMPARATOR
Intervention: MST retainers
Number of subjects: 85
Study: 22159928

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of methylcobalamin (500 mcg, 1 ml solution, three times a week for two weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1 ml normal saline)
Number of subjects: 60
Study: 17388705

Group type: EXPERIMENTAL
Intervention: Olanzapine (15-20 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Haloperidol (15-20 mg/day) with additional blinded benztropine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 35
Study: 15609384

Group type: EXPERIMENTAL
Intervention: Laparoscopic total fundoplication
Number of subjects: 107

Group type: COMPARATOR
Intervention: Laparoscopic anterior 180 degrees fundoplication
Number of subjects: 107
Study: 12141373

Group type: EXPERIMENTAL
Intervention: Vibration-induced white finger patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 10534586

Group type: EXPERIMENTAL
Intervention: 0-10 scales of current pain intensity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 0-10 scales of worst pain intensity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 0-10 scales of least pain intensity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 0-10 scales of average pain intensity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Composite measures of pain intensity
Number of subjects: 123
Study: 7499776

Group type: EXPERIMENTAL
Intervention: P. falciparum positive mothers' newborns
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Seropositive newborns
Number of subjects: 656

Group type: COMPARATOR
Intervention: Chloroquine prophylaxis
Number of subjects: 656